Sam Brusco, Associate Editor12.12.23
Haemonetics has completed its acquisition of OpSens, a cardiology-focused firm that features proprietary optical technology. The company acquired all outstanding OpSens shares for CAD $2.90 a share, representing equity value of about $255 million.
The company also increased fiscal year 2024 GAAP revenue growth guidance from 7-9% to 8-10%. Haemonetics expects OpSens to provide $55-65 million in revenue and be slightly accretive to earnings per diluted share, contributing about $0.10 to $0.15 in adjusted earnings per share.
The deal was first revealed two months ago.
OpSens’ core offerings include SavvyWire, which the company says is the world’s first, only three-in-one guidewire for TAVR (transcatheter aortic valve replacement) procedures that acts as both a pacing and pressure monitoring wire, and OptoWire, a pressure guidewire that measures Fractional Flow Reserve (FFR) and diastolic pressure ratio (dPR) to help diagnose and treat coronary artery disease.
OpSens also manufactures a range of fiber optic sensor products for medical devices and other critical, industrial applications. The acquisition of these products, Haemonetics said, fortifies its Hospital business portfolio in the interventional cardiology market. The company also said its Vascade vascular closure portfolio will
"Expanding our Hospital portfolio with OpSens' products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits," said Haemonetics' president and CEO Chris Simon. "We are pleased to officially welcome OpSens to Haemonetics and look forward to driving greater access to OpSens' essential solutions and benefits for physicians and patients throughout the world."
The company also increased fiscal year 2024 GAAP revenue growth guidance from 7-9% to 8-10%. Haemonetics expects OpSens to provide $55-65 million in revenue and be slightly accretive to earnings per diluted share, contributing about $0.10 to $0.15 in adjusted earnings per share.
The deal was first revealed two months ago.
OpSens’ core offerings include SavvyWire, which the company says is the world’s first, only three-in-one guidewire for TAVR (transcatheter aortic valve replacement) procedures that acts as both a pacing and pressure monitoring wire, and OptoWire, a pressure guidewire that measures Fractional Flow Reserve (FFR) and diastolic pressure ratio (dPR) to help diagnose and treat coronary artery disease.
OpSens also manufactures a range of fiber optic sensor products for medical devices and other critical, industrial applications. The acquisition of these products, Haemonetics said, fortifies its Hospital business portfolio in the interventional cardiology market. The company also said its Vascade vascular closure portfolio will
"Expanding our Hospital portfolio with OpSens' products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits," said Haemonetics' president and CEO Chris Simon. "We are pleased to officially welcome OpSens to Haemonetics and look forward to driving greater access to OpSens' essential solutions and benefits for physicians and patients throughout the world."